Skip to main content

Efficacy and safety of oliceridine versus remifentanil for analgesia in mechanically ventilated critically ill adults (CO-ROAM): a multicenter, assessor-blinded, non-inferiority randomized controlled trial

In brief

Oliceridine matches remifentanil analgesia, with respiratory depression in 0% vs 4.6%

In 304 mechanically ventilated adults, oliceridine kept patients in the target pain-control range for 96% of the time, compared with 92.3% on remifentanil, meeting the trial's non-inferiority standard. Respiratory depression and mild-to-moderate drug reactions were less frequent, and costs were lower, but ventilation duration, ICU stay, and mortality did not differ; confirmation beyond this trial remains important.

Journal
Intensive care medicine (Q1)
Published
10 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Sen Lu, Jing-Chao Luo, Qiang Li, Xian-Ying Lei, Xue-Feng Ding, Qiong-Lan Dong, et al.
PMID
43007421
DOI
10.1007/s00134-026-08643-8

Why clinicians should know about it

Abstract

PURPOSE: Remifentanil provides effective analgesia during invasive mechanical ventilation (IMV), but its utility is limited by opioid-related adverse events. Oliceridine, a G protein-biased μ-opioid receptor agonist, may decouple analgesia from these effects, but lacks evidence in critically ill patients. METHODS: This multicentre, assessor- and patient-blinded, non-inferiority randomised controlled trial was conducted across 19 intensive care units (ICUs) in China. Adults receiving IMV were randomised 1:1 to oliceridine or remifentanil, titrated to a Critical-Care Pain Observation Tool score below 3. The primary endpoint was time in target analgesic range (TTR; non-inferiority margin -10%). RESULTS: Of 307 randomised patients, 304 comprised the modified intention-to-treat population (151 oliceridine, 153 remifentanil). Median TTR was 96.0% versus 92.3% (absolute difference 3.7%, 95% CI -0.3-5.7%). Oliceridine was associated with fewer mild-to-moderate adverse drug reactions (ADRs), occurring at 15.9 versus 22.2 events per 100 patient-days (IRR 0.72, 95% CI 0.52-1.00, P = 0.049), and a lower rate of respiratory depression during the study period (0% vs. 4.6%, P = 0.015). Post-extubation respiratory depression (0% vs. 7.9%, P = 0.005) and analgesic-sedation costs were both lower with oliceridine. IMV duration, ICU stay, and 28-day mortality did not differ. Subgroup analyses identified a nominal ADR benefit in patients with Acute Physiology and Chronic Health Evaluation II > 17 and a larger nominal TTR difference in those without acute respiratory distress syndrome. CONCLUSION: Oliceridine provides non-inferior analgesia to remifentanil with a more favourable respiratory safety profile and lower costs in critically ill adults. TRIAL REGISTRATION: ClinicalTrials.gov NCT06454292 (registered June 11, 2024).

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.